Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Krystal Biotech, Inc. (NASDAQ: KRYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Krystal Biotech is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on genetic medicines such as VYJUVEK for dystrophic epidermolysis bullosa and a pipeline of investigational programs in respiratory, ophthalmology, dermatology, oncology, and aesthetics.
Through this page, users can review Form 8‑K current reports in which Krystal Biotech discloses material events. Recent 8‑K filings have covered quarterly financial results, commercial launches of VYJUVEK in new markets such as Japan, regulatory approvals, and key clinical milestones, including updates on trials for KB801 in neurotrophic keratitis and KB304 in aesthetics. These filings often incorporate press releases and slide presentations by reference, providing additional context on the company’s operational and clinical progress.
In addition to 8‑K reports, investors may use this page to navigate to Krystal Biotech’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which contain detailed information on its gene therapy platform, risk factors, financial statements, and segment information related to the development and commercialization of pharmaceutical products. For users interested in governance and compensation matters, proxy statements and related filings can also be accessed.
Stock Titan enhances these documents with AI-powered summaries that explain the key points of lengthy filings, helping readers quickly understand financial results, clinical updates, and regulatory developments without reading every page. Real-time integration with EDGAR ensures that new Krystal Biotech filings, including any future Forms 4 reporting insider transactions, 10‑Q, or 10‑K submissions, appear promptly, while AI-generated highlights point to sections that may be most relevant for KRYS shareholders and analysts.
Krystal Biotech insiders Krish S. Krishnan and Suma M. Krishnan jointly filed Amendment No. 3 to their Schedule 13G/A reporting an aggregate 3,388,283 shares of Common Stock, representing 11.5% of the class. The percentage is based on 29,479,756 shares outstanding as of April 29, 2026. The filing breaks down holdings as directly owned shares, shares held in family and spousal trusts, and stock options exercisable for 158,525 and 121,350 shares respectively. The Reporting Persons state shared voting and dispositive power over the aggregate amount and include a Joint Filing Agreement as Exhibit 99.1.
Krystal Biotech reported strong first quarter 2026 results, driven by VYJUVEK gene therapy sales and advancing its genetic medicine pipeline. VYJUVEK net product revenue reached $116.4 million in Q1 2026, a 32% increase over the prior-year quarter, with a gross margin of 95%.
Net income rose to $55.9 million, or $1.83 per diluted share, compared with $35.7 million, or $1.20 per diluted share, in Q1 2025. The company ended the quarter with a $1.0 billion cash and investment balance, supporting ongoing commercial and R&D activities.
Management highlighted global VYJUVEK uptake, including over 695 U.S. reimbursement approvals and growing European use, alongside multiple late-stage programs. Two ophthalmology registrational readouts are anticipated in 2026, and the FDA granted platform technology designation for KB407 and KB111, reinforcing the company’s HSV-1-based gene therapy platform.
Krystal Biotech, Inc. reported strong profitability for the quarter ended March 31, 2026, driven by rapid uptake of its gene therapy VYJUVEK. Product revenue, net rose to $116.4 million from $88.2 million a year earlier, largely from growth in Europe and Japan.
Gross margin was 95%, while net income increased to $55.9 million from $35.7 million. Diluted net income per share was $1.83, up from $1.20. Cash, cash equivalents and short-term investments totaled about $823.4 million, and the company reported retained earnings of $80.1 million, highlighting a solid balance sheet to fund its expanding clinical pipeline across ophthalmology, respiratory, dermatology, oncology and aesthetics.
Krystal Biotech Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 1,479,111 shares of Common Stock, representing 5.05% of the class. The filing states Vanguard has sole dispositive power over 1,479,111 shares and sole voting power for 22,384 shares.
The disclosure attributes holdings to Vanguard Portfolio Management and identified affiliates and notes these positions include shares held for Vanguard funds and managed accounts.
Krystal Biotech, Inc. reports a full-year Form 10-K describing a commercial-stage gene therapy company that launched its first approved product, VYJUVEK, in the U.S. (2023) and expanded launches to Europe and Japan in 2025. The report highlights $730.3 million in cumulative net product revenue since U.S. launch, global regulatory approvals and an advanced pipeline including inhaled KB407 for cystic fibrosis and inhaled KB707 for NSCLC. The company operates two in‑house CGMP facilities, reports an aggregate market value of common stock held by non-affiliates of $3.5 billion as of June 30, 2025, and had 29,232,189 shares outstanding as of February 11, 2026.
The filing details clinical progress across multiple programs, regulatory designations (ODD, RPDD, RMAT, FDA platform designation), commercialization status, manufacturing scale-up, and known program risks summarized under "Risk Factors."
Krystal Biotech Inc filing shows an amended Schedule 13G/A by The Vanguard Group reporting 0 shares and 0% beneficial ownership as of the filing; the amendment documents an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries for SEC reporting. The form is signed on 03/27/2026.
Krystal Biotech EVP Laurent Goux has filed an initial ownership report showing equity awards and stock holdings in Krystal Biotech, Inc. The Form 3 lists several grants of stock options and restricted stock units, plus common shares, all held directly as of March 1, 2026.
Stock option positions include grants covering 9,050, 7,449, 2,367, 4,750, 2,750 and 19,000 shares of common stock. Restricted stock unit awards include 3,628, 891 and 674 units, and he directly holds 919 shares of common stock.
The footnotes state that multiple option and RSU grants vest in four equal annual installments on the first through fourth anniversaries of their grant dates in 2023, 2024, 2025 and 2026, subject to his continued service, and note that one stock option grant for 19,000 shares is fully vested.
Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles filed an initial ownership report showing his equity interests in the company. This Form 3 does not report any new buy or sell transactions; it lists existing awards and holdings.
He directly holds several stock options, including one with 9,050 shares underlying common stock, and multiple restricted stock unit (RSU) awards, including 3,628 RSUs, along with 642 shares of common stock. Footnotes explain that the options and RSUs generally vest in four equal annual installments beginning around late February in 2024, 2025, and 2026, subject to his continued service, with one option already fully vested.
Krystal Biotech President of R&D and director Suma Krishnan sold 25,000 shares of the company’s common stock on March 4, 2026 in open-market trades under a pre-arranged Rule 10b5-1 trading plan. The reported sales occurred at prices between $256.68 and $266.93 per share.
After these transactions, she directly held 1,403,155 shares of Krystal Biotech common stock. She also had indirect ownership of 90,000 shares through SMK Trust and 50,000 shares through the Krishnan Family Trust, where she and her spouse are joint beneficial owners with joint voting and investment control.